Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: WHAT SYNERGIES COULD BE CREATED BETWEEN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENTS?

Presentation
Guido Rasi, Executive Director, European Medicines Agency (EMA), London, UK
Presentation
Wim Goettsch, Secretariat Director, EUnetHTA JA3, Diemen, The Netherlands
Presentation
Andrzej Rys, Director, Health Systems, Medical Products and Innovation, European Commission, Brussels, Belgium
Presentation
Jens Grueger, Vice President & Head of Global Pricing & Market Access, F. Hoffmann-LaRoche, Basel, Switzerland

 

SECOND PLENARY SESSION: DIFFERENTIAL PRICING OF MEDICINES IN EUROPE: IMPLICATIONS FOR ACCESS, INNOVATION, AND AFFORDABILITY

Presentation
Lou Garrison, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Presentation
Sabine Vogler, Program Coordinator, Pharmacoeconomics and Pharmaceutical Policy Analysis, Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria
Presentation
Jo De Cock, Chief Executive Officer, National Institute of Health and Disability Insurance (NIHDI), Brussels, Belgium
Presentation
Panos Kanavos, Associate Professor & Deputy Director, LSE Health, Department of Social Policy, London School of Economics, London, UK
Presentation
Adrian Towse, Director, Office of Health Economics, London, UK

 

THIRD PLENARY SESSION: HOW TO CONTROL COSTS AND IMPROVE ACCESS TO MEDICINES: LESSONS FROM THE INTERQUALITY PROJECT

Presentation
Tomasz Hermanowski, InterQuality Project Leader and Professor & Head, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
Presentation
Anna Zawada, Director, Transparency and Tariff Councils Office, Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland
Presentation
Axel Muehlbacher, Professor, Neubrandenburg University, Neubrandenburg, Germany
Presentation
Brian K. Solow, Chief Medical Officer, Optum Life Sciences, Irvine, CA, USA
Presentation
Joanna Lis, Director, Market Access, Sanofi-Aventis, Warsaw, Poland

 

ISSUE PANEL PRESENTATIONS

IP1 : PATIENT-CENTERED DECISION-MAKING WITH MULTI-CRITERIA DECISION ANALYSIS: SHOULD WE BE TRYING TO QUANTIFY THE PATIENT VOICE FOR USE IN HEALTH TECHNOLOGY ASSESSMENT?

Presentation
Lars Sandman, Professor, National Centre for Priority Setting in Health-Care, Linköping University, Linköping, Sweden
Presentation
Peter L. Kolominsky, Professor & Director, Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen - Nürnberg, Germany, Erlangen, Germany
Presentation
Alaa Hamed, Head, Rare Disease, Patient Outcomes and Medical Economics, Genzyme, a Sanofi Company, Cambridge, MA, USA

 

IP2 : NATIONAL HTA PROCESS AND EUROPEAN COOPERATION ON HTA--FIT FOR PURPOSE? (Invited Issue Panel)

Presentation
Zoe Garrett, Senior Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK
Presentation
Tomas Tesar, Member, Reimbursement Committee, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic
Presentation
Dominik Schnichels, Head of Unit, DG SANTE B4, Medical Products: Quality, Safety, Innovation, European Commission, Brussels, Belgium
Presentation
Rui Santos Ivo, Vice-President, Executive Board, National Authority of Medicines and Health Products (INFARMED), Lisbon, Portugal
Presentation
Finn Børlum Kristensen, Professor, University of Southern Denmark, Hilleroed, Denmark

 

IP4 : DOES EUROPEAN REAL WORLD DATA REQUIRE A ‘DIGITAL SCHENGEN’ TO SUPPORT FEDERATED ACCESS, ASSESSMENT, AND (RE)USE, OPENING BORDERS AT THE INSTITUTE TO CROSS-COUNTRY?

Presentation
Ömer Saka, Partner, Market Access Strategy and HEOR, Deloitte, Diegem, Belgium
Presentation
Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency, London, UK
Presentation
Sarah Garner, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK
Presentation
Johan van der Lei, Chair of the Department of Medical Informatics, Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

 

IP5 : A "FEDERAL" STANDARD FOR VALUING HEALTH IN A POST-REFERENDUM EUROPE?

Presentation
Ben van Hout, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Paul Kind, Professor, Centre for Health Economics, Management and Policy, HSE University, St. Petersburg, Russia
Meindert Boysen, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, and Programme Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

 

IP6 : FROM TESTIMONIALS TO QUALITATIVE RESEARCH EMBEDDED IN CLINICAL TRIALS: HOW DO HEALTH TECHNOLOGY ASSESSMENT BODIES CONSIDER THE VOICE OF RARE DISEASE PATIENTS WHEN GRANTING ACCESS TO ORPHAN DRUGS?

Presentation
Benoit Arnould, Senior Director, Patient-Centered Outcomes, Mapi Group, Lyon, France
Samantha Parker, Senior Vice President, Patient Access Officer, Lysogene, Neuilly sur Seine, France
Sheela Upadhyaya, Associate Director, Centre for Health Technology Evaluation, Highly Specialised Technologies, National Institute for Health and Care Excellence, London, UK
Christine Lavery, Group Chief Executive, The Society for Mucopolysaccharide Diseases, London, UK

 

IP7 : HOW SHOULD BIOSIMILARS BE VALUED AND SHOULD THEY UNDERGO HEALTH TECHNOLOGY ASSESSMENT?

Presentation
Andrew Walker, Health Economist, Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
Jeanette Kusel, Head of HTA and Health Economics, Costello Medical Consulting Ltd, Cambridge, UK
Emi Psachoulia, Senior Manager Market Access, Biogen International GmbH, Zug, Switzerland
Frank McKenna, Consultant Rheumatologist, Trafford General Hospital, Central Manchester University Hospitals, Manchester, UK

 

IP8 : IS THE GOAL OF UNIVERSAL COMPARATIVE EFFECTIVENESS EVIDENCE ACROSS JURISDICTIONS ACHIEVABLE?

Presentation
Sarah Garner, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK
Rob Thwaites, Senior Director, Takeda, London, UK
Pall Jonsson, Senior Scientific Adviser, Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE), Manchester, UK
Hans-Georg Eichler, Senior Medical Officer EMA, European Medicines Agency, London, UK

 

IP9 : INCENTIVISING RESEARCH INTO THE EFFECTIVENESS OF MEDICAL DEVICES

Presentation
Michael F Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Adrian Griffin, Vice President HTA & Reimbursement Policy, Johnson & Johnson, High Wycombe, UK
Presentation
Rosanna Tarricone, Professor, Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy
Presentation
Mirella Marlow, Programme Director, Devices and Diagnostics Systems, NICE (National Institute for Health and Clinical Excellence), London, UK

 

IP10 : ADAPTIVE PATHWAYS AND PATIENT ACCESS – PUSHING PAYER BOUNDARIES OR FACILITATING NEW PAYMENT MODELS?

Presentation
Jacoline Bouvy, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK
Presentation
Claudine Sapede, Global HTA & Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland

 

IP11 : EMERGING US VALUE FRAMEWORKS: ARE THERE LESSONS FROM - OR FOR - EUROPE? (Invited Issue Panel)

Presentation
Michael F Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Richard J. Willke, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA
Presentation
Finn Børlum Kristensen, Professor, University of Southern Denmark, Hilleroed, Denmark
Presentation
Peter J. Neumann, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts University, Boston, MA, USA

 

IP12 : VALUING TRANSFORMATIVE MEDICINES IN RARE DISEASES: METHODS AND MADNESS

Presentation
Alastair Kent, Director, Genetic Alliance UK, London, UK
Paul Hodgkins, Vice President, Vertex Pharmaceuticals Incorporated, Boston, MA, USA
Ron Akehurst, Strategic Director, BresMed Health Solutions, Sheffield, UK
Maarten Postma, Professor Pharmacoeconomics, Pharmacy Dept, University of Groningen, Groningen, The Netherlands

 

IP14 : EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES?

Presentation
Rok Hren, Assistant Professor, University of Ljubljana, Ljubljana, Slovenia
Presentation
Tomas Tesar, Member of the Reimbursement Committee of the Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovakia
Presentation
Andras Inotai, Senior Pharmacoeconomist, Syreon Research Institute, Budapest, Hungary
Presentation
Duša Hlade Zore, Representative of Patients’ Rights, Ministry of Health, Government of the Republic of Slovenia, Ljubljana, Slovenia

 

IP15 : IS BALANCING VALUE DEMONSTRATION FOR PAYER AND PATIENT INTERESTS A FEASIBLE NOTION?

Presentation
Kathleen E. Hughes, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA
Presentation
Sachin Kamal-Bahl, Vice President & Head, Global Health & Value Innovation Center, Pfizer, Collegeville, PA, USA
Presentation
Adrian Towse, Director, Office of Health Economics, London, UK

 

IP16 : SHOULD HEALTH TECHNOLOGY ASSESSMENT GUIDELINES RECOMMEND INCLUSION OF FUTURE MEDICAL COSTS?

Presentation
Pieter van Baal, Associate Professor, Institute for Health Policy and Management (iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands
Presentation
Andrew Briggs, William R Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK
Presentation
Alec Morton, Professor, Management Science, University of Strathclyde, Glasgow, UK
Presentation
Ad Antonisse, Director Economic Affairs (Market Access & Public Affairs), AstraZeneca, Zoetermeer, The Netherlands

 

IP17 : CAN WE REALLY COMPARE AND AGGREGATE PATIENT-REPORTED OUTCOME DATA BETWEEN PEOPLE AND SETTINGS? IMPLICATIONS FOR CLINICAL TRIALS AND HEALTH TECHNOLOGY ASSESSMENT

Presentation
Andrea Manca, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Nancy Devlin, Director of Research, Office of Health Economics, London, UK
Presentation
Michael Herdman, Director, Insight Consulting and Research, Mataró, Spain
Presentation
Paula Lorgelly, Deputy Director, Office of Health Economics, London, UK

 

IP18 : PATIENT PREFERENCES IN DRUG EVALUATION: WHICH METHOD SHOULD WE USE?

Presentation
Heather L. Gelhorn, Senior Research Scientist, Outcomes Research, Evidera, Bethesda, MD, USA
Presentation
Douwe Postmus, Researcher, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Presentation
Tommi Tervonen, Senior Research Associate, Evidera Ltd, London, UK

 

IP19 : USING OBSERVATIONAL (‘REAL WORLD’) DATA IN HEALTH TECHNOLOGY ASSESSMENT: ROUTE TO CONFUSION OR BETTER DECISIONS?

Presentation
Michael Seewald, Global Head Real World Evidence, Novartis, Basel, Germany
Presentation
Keith R Abrams, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK
Presentation
Sarah Garner, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK
Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics & Director, Programme on Economic Evaluation and Health Technology Assessment, University of York, Heslington, York, UK

 

IP21 : IS OFF-LABEL DRUG USE ENHANCING OR LIMITING ACCESS FOR PATIENTS WITH RARE DISEASES?

Presentation
Annabel Griffiths, Consultant, Costello Medical Consulting Ltd, Cambridge, UK
Oliver Timmis, CEO, AKU Society, Cambridge, UK
Jack Scannell, Co-head European Pharmaceuticals, UBS Investment Bank, London, UK
Pilar Pinilla-Dominguez, Technical Adviser, NICE Scientific Advice, National Institute for Health and Care Excellence, London, UK

 

WORKSHOP PRESENTATIONS

W1 : THE NEW NICE CANCER DRUGS FUND TECHNOLOGY APPRAISAL PROCESS: YOUR QUESTIONS ANSWERED

Presentation
Meindert Boysen, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK
Caroline Ling, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK
David Tyas, Associate Director, Health Economics and Outcomes Research, Bristol-Myers Squibb, Uxbridge, UK
Sorrel Wolowacz, Head, European Health Economics, RTI Health Solutions, Manchester, UK

 

W2 : MOVING THE SCIENCE FORWARD: PSYCHOMETRIC CONSIDERATIONS AND STUDY DESIGNS FOR UNDERSTANDING MEANINGFUL CHANGE AND CONDUCTING MIXED METHODS RESEARCH

Presentation
Tara Symonds, COA Strategy Lead & Partner, Clinical Outcomes Solutions Ltd., Folkestone, Kent, UK
Lori McLeod, Director of Psychometrics, RTI Health Solutions, Research Triangle Park, NC, USA
Stacie Hudgens, Managing Partner, Strategic Lead, Clinical Outcomes Solutions, Tucson, AZ, USA
Cheryl Coon, Principal, Outcometrix, Tucson, AZ, USA

 

W3 : UTILITIES IN ECONOMIC EVALUATION: USING BEST PRACTICES WHERE INTERNATIONAL GUIDELINES PROVIDE INSUFFICIENT DETAIL

Presentation
Roberta Ara, Senior Research Fellow, School of Health and Related Research, The University of Sheffield, Sheffield, UK
Presentation
Helene Chevrou-Severac, Global Head of Health Economics and HTA, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland

 

W4 : UNDERSTANDING THE CHALLENGES FACING THE VALUE ASSESSMENT OF MEDICAL DEVICES

Presentation
Richard Charter, Head of Market Access & Pricing Diabetes Care Europe, Becton Dickinson AG, Allschwil, Switzerland
Carla Zema, Director, Health Policy and Economics, ZOLL, Pittsburgh, PA, USA
Chantale Lessard, Adjunct Professor, Department of Health Management, Evaluation and Policy, School of Public Health, University of Montreal, Montreal, QC, Canada

 

W5 : NEW APPROACHES TO SURVIVAL MODELING IN ONCOLOGY

Presentation
Jack Ishak, Senior Research Leader, Modeling & Simulation, Evidera, Montreal, QC, Canada
Presentation
Aline Gauthier, Managing Director, Health Economics and Market Access, Amaris, London, UK
Presentation
Victoria Federico Paly, Senior Health Economist, ICON Health Economics & Epidemiology, New York, NY, USA
Presentation
Federico Felizzi, HTA Statistician, GPMA, F. Hoffmann La Roche, Basel, Switzerland

 

W6 : BRIDGING THE GAP BETWEEN EFFICACY AND EFFECTIVENESS: METHODS TO IDENTIFY DRIVERS OF EFFECTIVENESS BEFORE LAUNCH

Presentation
Clementine Nordon, Senior Epidemiologist, LASER Analytica, Paris, France
Chris Chinn, Head of Real World Investigations, Sanofi, Guildford, UK
Lifang Liu, Epidemiologist, EORTC, Brussels, Belgium

 

W7 : APPROPRIATE MODEL TIME HORIZONS: THEORY, EMPIRICAL RESULTS, AND THE PERSPECTIVE OF DECISION MAKERS

Presentation
Anthony J Hatswell, Principal Consulting Economist, Department of Statistical Science, University College London, London, UK
Uwe Siebert, Professor & Chair, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Austria, Adjunct Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria
Ash Bullement, Health Economist, BresMed Health Solutions, Sheffield, UK
Matthew Taylor, Director, York Health Economics Consortium, Heslington, York, UK

 

W8 : THE IMPORTANCE OF RELEVANCE IN HEALTH ECONOMIC EVALUATIONS: CHALLENGES AND WAYS FORWARD

Presentation
Manuela A. Joore, Professor of Health Technology Assessment & Decision Making, Department of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands
Presentation
Herbert J.A. Rolden, Postdoctoral Researcher, Radboud Institute for Health Sciences, Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands
Presentation
J. Jaime Caro, Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal and Chief Scientist, Evidera, Inc., Lexington, MA, USA

 

W11 : LET'S GO FLY A KITE - MANAGING THE WINDS OF CHANGE IN REAL WORLD EVIDENCE STUDIES

Presentation
Alison Bourke, Scientific Director Real-World Evidence Solutions, IMS Health, London, UK
Presentation
Gillian C Hall, Consultant in Pharmacoepidemiology, Gillian Hall Epidemiology Ltd, London, UK
Presentation
Andrew Bate, Senior Director, Epidemiology Group Lead, Analytics & Worldwide Safety, Pfizer Ltd, Surrey, UK

 

W12 : RETHINKING WHAT MISSING PATIENT-REPORTED OUTCOME (PRO) DATA CAN TEACH US ABOUT OUTCOMES AND SURVIVAL IN ONCOLOGY CLINICAL TRIALS

Presentation
Mark E. Boye, Principal Scientist, Eli Lilly and Company, Indianapolis, IN, USA
Katherine Houghton, Associate Director, Health Economics, RTI Health Solutions, Durham, NC, USA
Donald E Stull, Head, Data Analytics and Design Strategy, Health Economics, RTI Health Solutions, Durham, NC, USA

 

W13 : CHANGING OUR PERSPECTIVE ON PATIENT-REPORTED OUTCOMES IN ONCOLOGY: IT’S MORE COMPLEX THAN TRADITIONALLY CONCEPTUALIZED OR ANALYZED

Presentation
Mark E. Boye, Principal Scientist, Eli Lilly and Company, Indianapolis, IN, USA
Donald E Stull, Head, Data Analytics and Design Strategy, Health Economics, RTI Health Solutions, Durham, NC, USA
Claire Ainsworth, Research Analyst, Health Economics, RTI Health Solutions, MANCHESTER, UK

 

W14 : CHOICE DEFINES VALUE: HOW TO ANALYSE AND DISSEMINATE EVIDENCE ON THE IMPORTANCE OF MULTIPLE CRITERIA FROM MULTIPLE PERSPECTIVES TO INFORM AN APPRAISAL PROCESS IN HEALTH TECHNOLOGY ASSESSMENT

Presentation
Juan Marcos Gonzalez, Senior Research Economist, RTI Health Solutions, Research Triangle Park, NC, USA
Axel Mühlbacher, Professor, Health Economics and Health Care Management, IGM, Hochschule Neubrandenburg, Neubrandenburg, Germany
Benjamin M. Craig, Associate Professor, Department of Economics, University of South Florida and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
Juan Manuel Ramos-Goñi, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands

 

W15 : BUILDING AND APPLYING CONSTRAINED OPTIMIZATION MODELS IN HEALTH CARE: A CASE STUDY OF OPTIMAL KIDNEY MATCHING

Presentation
William H. Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Alec Morton, Professor, Management Science, University of Strathclyde, Glasgow, UK
Praveen Thokala, Research Fellow, Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
William V. Padula, Assistant Professor, Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

 

W16 : HOW TO TRANSFER ECONOMIC EVIDENCE TO LOW AND MIDDLE-INCOME COUNTRIES? WORKING UNDER CAPACITY RESTRICTIONS

Presentation
Johan L. Severens, Professor of Evaluation in Health Care, Institute of Health Policy & Management, Institute of Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Presentation
Zoltan Kalo, Professor of Health Economics & Head of the Institute of Economics, Eötvös Loránd University, Budapest, Hungary
Presentation
Olena Mandrik, Postdoc Researcher, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
Presentation
Saskia Knies, Advisor Pharmacoeconomics, National Health Care Institute, Diemen, The Netherlands

 

W17 : NEW CHALLENGES FOR HIGH-RISK MEDICAL DEVICES IN EUROPE: HOW TO ACHIEVE THE BALANCE BETWEEN THE DEMAND FOR EARLY PRODUCT LAUNCH AND SAFETY?

Presentation
Jenifer Ehreth, Executive & Scientific Vice President, LASER Analytica, Paris, France
Presentation
Rosanna Tarricone, Professor, Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy
Presentation
Bernard Avouac, Former president of Transparency Commission, Medecin des Hopitaux de Paris, Paris, France

 

W18 : METHODOLOGIES FOR EVALUATING GEOGRAPHIC VARIATION IN HEALTH CARE OUTCOMES RESEARCH

Presentation
Gregoire Mercier, Head, Economic Evaluation Unit, CHU Montpellier, Montpellier, France
Vera Georgescu, Head, Economic Evaluation Unit, CHU Montpellier, Montpellier, France

 

W19 : STRENGTHENING THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH TECHNOLOGY ASSESSMENT: KNOWN CHALLENGES AND PROPOSED SOLUTIONS

Presentation
Elisabeth Fenwick, Principal of Health Economics, ICON Health Economics & Epidemiology, Abingdon, UK
Presentation
Claire Rothery, Senior Research Fellow in Health Economics, Centre for Health Economics, University of York, York, UK
Presentation
David Glynn, PhD student, Centre for Health Economics, University of York, York, UK

 

W20 : PREDICTING TREATMENT EFFECTIVENESS OVER TIME IN REAL WORLD FROM TRIAL EFFICACY DATA

Presentation
Keith Abrams, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK
Presentation
Eva-Maria Didden, Researcher, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Presentation
Mark Belger, Principal Research Scientist, GSS, Eli Lilly, Ascot, UK

 

W21 : DOUBLY ROBUST ESTIMATION FOR COMPARATIVE EFFECTIVENESS RESEARCH: GETTING AN EXTRA SHOT AT CORRECTLY SPECIFYING THE TREATMENT-OUTCOME MODEL

Presentation
Valéry Risson, Director, HEOR Excellence, Novartis Pharma AG, Basel, Switzerland
Patrick Lefebvre, Managing Principal, Groupe d'analyse, Ltée, Montreal, QC, Canada
Maral DerSarkissian, Associate, Analysis Group, Inc., Los Angeles, CA, USA
Melvin "Skip" Olson, Head, RWD Strategy and Innovation, Novartis Pharma AG, Basel, Switzerland

 

W22 : VALUE OF INFORMATION ANALYSIS TO SUPPORT COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEMES: INDUSTRY VERSUS PAYER PERSPECTIVE

Presentation
Saskia Knies, Policy Advisor Health Economics, National Health Care Institute (ZiN), Diemen, The Netherlands
Presentation
Leyla Mohseninejad, HEOR Manager, Creativ-Ceutical, Rotterdam, The Netherlands
Presentation
Mondher Toumi, Professor, Public Health Department, Aix-Marseille University, Marseille, France

 

W23 : ALL MODELS ARE WRONG, BUT SOME ARE LESS WRONG: USING A VERIFICATION PROTOCOL TO FIND THESE LESS WRONG ONES ON THE MODEL FARM?

Presentation
Maiwenn J. Al, Assistant Professor, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Presentation
Dawn Lee, Head of Health Economics Analysis, BresMed Health Solutions, Sheffield, UK
Presentation
Nasuh Buyukkaramikli, Senior Researcher, Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands
Presentation
Rachid Rafia, Senior Researcher, Sheffield University, Sheffield, UK

 

W24 : ADAPTING TO EVOLVING EVIDENCE REQUIREMENTS IN GLOBAL MEDICAL DEVICE DEVELOPMENT PROGRAMS

Presentation
Mark Campbell, Associate Director - Medical Technologies Evaluation Programme, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, UK, Manchester, UK
Thomas Goss, Sr. Vice President, Boston Healthcare Associates, Boston, MA, USA
Pascale Brasseur, Global Health Economics & Reimbursement Director, Spine & Biologics, Medtronic plc, Tolochenaz, Switzerland
Moore Matt, Director, Global Health Economics and Reimbursement, Edwards Lifesciences, Irvine, CA, USA

 

W25 : SPHERE OF INFLUENCE: RUSSIA'S EMERGING HEALTH TECHNOLOGY ASSESSMENT AND ITS INFLUENCE OVER ACCESS IN CIS COUNTRIES

Presentation
Cyrus A. Chowdhury, CEO & Managing Director, CBPartners, New York, NY, USA
Elena Subbotina, Consultant, CBPartners, London, UK
Malwina Holownia, Senior Health Economist, Moscow Department of Health, Moscow, Russian Federation

 

W26 : BIOSIMILAR VALUE GENERATION OR VALUE DESTRUCTION? A WORKSHOP DEMONSTRATING UPTAKE TO DATE AND QUANTIFYING SAVINGS MADE

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Monique Martin, Managing Director PMA Europe, inVentiv Health, London, UK

 

W27 : GUIDELINES FOR ANALYZING PUBLISHED SUMMARY TIME TO EVENT DATA

Presentation
Arman Altincatal, Senior Statistician, Evidera, Lexington, MA, USA
Martin Hoyle, Associate Professor of Health Economics, Medical School, University of Exeter, Exeter, UK
Jack Ishak, Senior Research Leader, Modeling and Simulation, Evidera, Montreal, QC, Canada

 

W28 : HEALTH-ECONOMIC EVALUATION OF GENOMIC TECHNOLOGIES: WHICH ISSUES ARISE?

Presentation
Gerardus WJ Frederix, Post-doc, Julius Centre, Utrecht University, Utrecht, The Netherlands
Presentation
Sarah Wordsworth, Associate Professor, Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
Presentation
Rene Sluiter, PhD Student, Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands
Presentation
Kjm van Nimwegen, PhD Student, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands

 

W30 : MEASURING MULTIPLE MEDICATION ADHERENCE – WHICH MEASURE WHEN?

Presentation
Maria Malmenäs, Director Hemu, HERON Commercialization, PAREXEL International, Stockholm, Sweden
Bryan Bennett, Director, Patient Centered Outcomes, Adelphi Values Ltd, Bollington, UK
Priti Pednekar, PhD Student, Health Policy, University of the Sciences, Philadelphia, PA, USA
Tamas Agh, Principal Researcher, Syreon Research Institute, Budapest, Hungary

 

W31 : DETERMINING UTILITY OF MULTI-ATTRIBUTE HEALTH STATES: NEW MEASUREMENT AND ANALYTIC APPROACHES

Presentation
Kim Rand-Hendriksen, Post-Doctoral Fellow, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway
Mark Oppe, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands
Juan Manuel Ramos Goñi, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands
Nan Luo, Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

 

W32 : HOW TO INCORPORATE ECONOMIC EVALUATIONS IN CLINICAL PRACTICE GUIDELINES: A PRACTICAL WORKSHOP ON RESEARCH METHODS

Presentation
Jos Kleijnen, Professor, Kleijnen Systematic Reviews Ltd., York, UK
Ghislaine APG van Mastrigt, Senior HTA Researcher, Department of Health Services Research, Maastricht University, Maastricht, The Netherlands
Ben Wijnen, HTA researcher, Department of Health Services Research, Maastricht University, Maastricht, The Netherlands
Frederick Thielen, HTA Researcher, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

 

ISPOR FORUMS

F1 : EXTENDING COST-EFFECTIVENESS ANALYSIS, PARTIAL OPTIMIZATION MODELLING, AND FISCAL MODELLING IN VACCINE VALUE ASSESSMENTS

Presentation
Raymond Hutubessy, Senior Health Economist, Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland
Presentation
Baudouin Standaert, Director, Health Economics, GSK Vaccines, Wavre, Belgium
Presentation
Hans Severens, Professor, Evaluation in Health Care, iBMG - Institute of Health Policy & Management and iMTA - Institute of Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

 

F2 : PATIENT ENGAGEMENT: STOPPING TO DEFINE IT

Presentation
Russell Wheeler, Patient Advocate, Leber Hereditary Optic Neuropathy, Winchester, UK
Maya L. Hanna, Doctoral Student, School of Pharmacy, University of Maryland, Baltimore, MD, USA
Rob Camp, Communications Manager, European Patients' Academy (EUPATI), Barcelona, Spain
Todd Berner, Head Global Medical Affairs Strategy, Immunology, Baxalta, Bannockburn, IL, USA

 

F3 : GENERATING EVIDENCE OF THE ADDED VALUE OF ‘PRECISION’ MEDICINE

Presentation
Katherine Payne, Professor of Health Economics, The University of Manchester, Manchester, UK
Uwe Siebert, Professor & Chair, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Austria, Adjunct Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria
Anke-Peggy Holtorf, Managing Director, Health Outcomes Strategies, GmbH, Basel, Switzerland
Gurmit Sandhu, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland
Eric Faulkner, Vice President, Precision and Transformative Technology Solutions, Value Demonstration, Access and Commercial, Evidera, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, SC, USA

 

F4 : BURDEN OF HEPATITIS C IN CENTRAL AND EASTERN EUROPEAN COUNTRIES

Presentation
Guenka Petrova, Professor, Social Pharmacy, Medical University Sofia, Faculty of Pharmacy, and President, ISPOR Bulgaria Chapter, Sofia, Bulgaria
Presentation
Anush Perikhanyan, Researcher, Pharmaceutical Management, Yerevan State Medical University, and President, ISPOR Armenia Chapter, Yerevan, Armenia
Presentation
Lubov Krasnova, Senior Researcher, Department of Hematology & Geriatrics, First Sechenov State Medical University, Moscow, Russian Federation
Presentation
Zoltán Kaló, Professor of Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary
Presentation
Elena Pyadushkina, Researcher, Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

 

F5 : DRUG PRICING IN ADRIATIC COUNTRIES – IS REFERENCE PRICING THE BEST OPTION?

Presentation
Rok Hren, Professor, University of Ljubljana, Ljubljana, Slovenia
Presentation
Tarik Catic, Past President, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
Presentation
Pero Draganić, President, ISPOR Croatia Chapter, and Assistant Professor, HALMED, Zagreb, Croatia
Presentation
Dragana Atanasijevic, President, ISPOR Serbia Chapter, and Consultant, HTA & Healthcare Quality Improvement, Belgrade, Serbia

 

F6 : THE ECONOMIC BURDEN OF COUNTERFEIT MEDICINES IN AFRICA: SITUATION ANALYSIS AND PROPOSED SOLUTIONS

Presentation
Mahmoud Diaa Elmahdawy, President, ISPOR Egypt Chapter, Director, AMAC Market Access, Novartis, Health Economics, and Lecturer of Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt
Presentation
Ilse Truter, Professor in Pharmacy & Leader, Drug Utilization Research Unit (DURU), Department of Pharmacy, School of Medicinal Sciences, Faculty of Health Sciences, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Presentation
Kasem Akhras, Head, Market Access, Middle East and North Africa (MENA), Novartis Pharma Services AG, Dubai, United Arab Emirates

 

F7 : A STRUCTURED DEBATE REGARDING THE NATIONAL HEALTH ECONOMICS GUIDELINES IN SOUTHERN EUROPE

Presentation
Francesco Saverio Mennini, Professor, Faculty of Economics, Centre for Economic Evaluation and HTA (EEHTA), CEIS, University of Rome Tor Vergata, Rome, Italy
Presentation
Carlos Gouveia Pinto, Associate Professor, ISEG, Lisbon School of Economics and Management and President, ISPOR Portugal Chapter, Lisbon, Portugal
Presentation
Luis Silva Miguel, Researcher, Research Centre on the Portuguese Economy, CISEP, Lisbon School of Economics & Management, University of Lisbon, Lisbon, Portugal
Presentation
Jaime Espín, Professor, Andalusian School of Public Health, Granada, Spain
Presentation
Lorenzo G. Mantovani, Associate Professor of Public Health, Research Centre on Public Health, University of Milano-Bicocca, Monza, Italy

 

F8 : NEW ISSUES & EMERGING TRENDS IN HEOR: REVISING THE ISPOR CODE OF ETHICS

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Louise Parmenter, Vice President, Epidemiology & Outcomes Research, Real-World & Late Phase Research, Quintiles, Inc., Reading, UK
Jessica Santos, Global Compliance and Quality Director, Kantar Health, Epsom, UK
Richard J. Willke, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA
Gurmit Sandhu, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland

 

F9 : USES, APPLICATIONS, AND FUTURE DIRECTIONS OF THE ISPOR DIGEST OF INTERNATIONAL DATABASES

Presentation
Elisabeth M. Oehrlein, PhD Candidate, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA
Brian Seal, Director, Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
Carl Asche, Director, University of Illinois College of Medicine, Center for Outcomes Research, Peoria, IL, USA

 

F10 : HEALTH ECONOMIC MODELING IN ONCOLOGY

Presentation
Noemi Muszbek, Senior Research Scientist, Evidera, London, UK
Sorrel Wolowacz, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK
Agnes Benedict, Executive Director, Evidera, Budapest, Hungary

 

F11 : RESULTS FROM MCDA PAYER CRITERIA: WEIGHTS & PREFERENCES IN THE CEE REGION

Presentation
Oresta Piniazhko, PhD Candidate & Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
Tomas Dolezal, Scientific Director, Institute of Health Economics and Technology Assessment, iHETA, Prague, Czech Republic
Presentation
Aleksandra Zawodnik, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Presentation
Ioannis Yfantopoulos, President, ISPOR Greece Chapter, and Professor of Health Economics, Economics and Political Science, University of Athens, Athens, Greece

 

F12 : THE VALUE OF MULTI-STAKEHOLDER PARTNERSHIP IN ADVANCING PATIENT ACCESS IN CENTRAL AND EASTERN EUROPE

Presentation
Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium
Presentation
Tamas Agh, Principal Researcher, Syreon Research Institute, Budapest, Hungary
Presentation
Stanimir Hasurdjiev, Secretary-General, Patient Access Partnership, Brussels, Belgium
Presentation
Martin Višňanský, Lecturer, University of Veterinary Medicine and Pharmacy, Kosice, Slovakia

 

F13 : THE SPANISH EXPERIENCE IN HEPATITIS C: FRIENDS OR FOES?

Presentation
Pedro Gómez-Pajuelo, Health Economist, Ministry of Health, Madrid, Spain
Presentation
Álvaro Hidalgo, Professor, Universidad de Castilla la Mancha, Toledo, Spain

 

EDUCATIONAL SYMPOSIA

INCREASING EUROQOL (EQ-5D) FROM 3 TO 5 LEVELS: IMPLICATIONS FOR USERS - DOES "NEW" MEAN "BETTER"?

Presentation
Bas Janssen, Senior Researcher, EuroQol Office, EuroQol Research Foundation, Rotterdam, The Netherlands
Presentation
Andrew Lloyd, Director, Bladon Associates Ltd, Oxford, UK
Presentation
Allan Wailoo, Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, UK

 

VALUE OPTIMIZATION IN HCV: BEYOND HEALTH ECONOMICS

Presentation
Zoltan Kalo, Professor of Health Economics & Head of the Institute of Economics, Eötvös Loránd University, Budapest, Hungary
Homie Razavi, Managing Director, Center for Disease Analysis, Denver, CO, USA
Rafael Bengoa, Director, Institute for Health & Strategy, Bilbao, Spain

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 19th Annual European Congress, see: the ISPOR Scientific Presentations Database an electronic database of nearly 39,500 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 19th Annual European Congress – Vienna, Austria
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS

OPEN MEETING: STATISTICAL METHODS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH SPECIAL INTEREST GROUP

OPEN MEETING: PATIENT ENGAGEMENT, PATIENT CENTRIC, WHAT DOES IT ALL MEAN?

EDUCATIONAL FORUM
STUDENT SHOWCASE

HAVING A HIGH IMPACT ON MANAGING ACCESS TO MEDICAL INNOVATION: STRENGTHENING THE METHODOLOGY-POLICY NEXUS

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.